KNOXVILLE, TN, July 10, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting, held in Munich, Germany from June 28-29.

The presentation, entitled “Current Clinical Trials with PV-10 (Rose Bengal), The First Small Molecule Oncolytic Immunotherapy,” was made by Sanjiv Agarwala, MD, Chief of Medical Oncology & Hematology, St. Luke’s Cancer Center and Professor of Medicine, Temple/St. Luke’s School of Medicine, Bethlehem, Pennsylvania, during the meeting’s Intralesional Treatments session. A copy of the presentation is available on Provectus' website at https://www.provectusbio.com/media/docs/publications/2018-06-PV-10-Munich.pdf.

Dominic Rodrigues, Vice Chair of the Company's Board of Directors, said, “Of the several hundred patients who have received PV-10 in multiple treatment settings, the majority have been melanoma patients who received the investigational drug as a monotherapy or part of a combination therapy.”

Mr. Rodrigues added, “This substantial and substantive melanoma experience enabled Provectus to build a clinical development platform that has investigated PV-10’s anti-cancer potential in at least a dozen more types of solid tumor disease, in monotherapy and combination therapy settings, and in adults and children. These newer non-clinical and clinical areas, where PV-10 may exhibit similar immune activity, include non-melanoma skin cancers, hepatocellular carcinoma and other gastrointestinal cancers, women’s cancers, and pediatric cancers.”

About PV-10

Provectus’ lead investigational oncology drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.

About Provectus

Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company leading the development of a new class of drugs based on halogenated xanthenes. Information about the Company’s clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017).

Contact:
Provectus Biopharmaceuticals, Inc.
Tim Scott, Ph.D.
President
Phone: (866) 594-5999